Partners Innovation
SelectiveCambridge, MABiotechnology, Healthcare, PharmaceuticalsLast fund filed October 2016
4 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Partners Innovation Fund II, L.P. | October 2016 | $66M | $66M | 15 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
4 partners are named across this firm’s filings, 4 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Julius Knowles | Selective | Biotech & pharma, Enterprise software | 6 | 2 |
Classified sectors of Partners Innovation’s own portfolio companies, based on 20 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| New Leaf | 2 | Abcuro, QPID |
| Atlas Venture | 1 | Annovation BioPharma |
| Caduceus Capital | 1 | Keros Therapeutics |
| Orbimed Asia Partners | 1 |
| Roger Kitterman | Slowing | Digital health, Biotech & pharma | 4 | 1 |
| Carl Berke | Quiet | Biotech & pharma, Consumer apps & internet, Digital health | 5 | 0 |
| Meredith Fisher | Quiet | Biotech & pharma, Climate & energy | 9 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Partners Innovation’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Keros Therapeutics |
| Orbimed Genesis | 1 | Keros Therapeutics |
| Orbimed Global Healthcare | 1 | Keros Therapeutics |
| Orbimed Israel Partners | 1 | Keros Therapeutics |
| Orbimed New Horizons | 1 | Keros Therapeutics |
| Orbimed Partners | 1 | Keros Therapeutics |
| Orbimed Private Investments | 1 | Keros Therapeutics |
| Transformation Capital | 1 | CodaMetrix |
| Westlake Biopartners | 1 | Albamunity |
A shared board seat: a company where filings name a Partners Innovation partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.